- Home
- VRTX vs APO Comparison
VRTX vs APO Comparison
Compare VRTX & APO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- APO
- Stock Information
- Founded
- VRTX 1989
- APO 1990
- Country
- VRTX United States
- APO United States
- Employees
- VRTX N/A
- APO N/A
- Industry
- VRTX EDP Services
- APO Investment Managers
- Sector
- VRTX Technology
- APO Finance
- Exchange
- VRTX Nasdaq
- APO Nasdaq
- Market Cap
- VRTX 96.6B
- APO 77.6B
- IPO Year
- VRTX 1991
- APO 2011
- Fundamental
- Price
- VRTX $434.67
- APO $130.00
- Analyst Decision
- VRTX Buy
- APO Strong Buy
- Analyst Count
- VRTX 26
- APO 14
- Target Price
- VRTX $489.17
- APO $163.57
- AVG Volume (30 Days)
- VRTX 1.4M
- APO 3.5M
- Earning Date
- VRTX 11-03-2025
- APO 11-04-2025
- Dividend Yield
- VRTX N/A
- APO 1.58%
- EPS Growth
- VRTX N/A
- APO N/A
- EPS
- VRTX 14.22
- APO 6.87
- Revenue
- VRTX $11,723,300,000.00
- APO $27,217,000,000.00
- Revenue This Year
- VRTX $10.95
- APO N/A
- Revenue Next Year
- VRTX $9.55
- APO $16.21
- P/E Ratio
- VRTX $30.55
- APO $18.75
- Revenue Growth
- VRTX 10.33
- APO N/A
- 52 Week Low
- VRTX $362.50
- APO $102.58
- 52 Week High
- VRTX $519.68
- APO $189.49
- Technical
- Relative Strength Index (RSI)
- VRTX 63.79
- APO 49.77
- Support Level
- VRTX $406.67
- APO $126.99
- Resistance Level
- VRTX $430.71
- APO $137.03
- Average True Range (ATR)
- VRTX 11.47
- APO 4.12
- MACD
- VRTX 0.70
- APO 0.89
- Stochastic Oscillator
- VRTX 82.90
- APO 45.98
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About APO Apollo Global Management Inc. (New)
Apollo Asset Management, Inc., formerly Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Asset Management, Retirement Services, and Principal Investing. It generates maximum revenue from the Retirement Services segment.